Market Overview

UPDATE: Goldman Sachs Reinstates Coverage on Warner Chilcott with Neutral Rating, $19 PT

Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

In a report published Wednesday, the Goldman Sachs Group reinstated coverage on Warner Chilcott (NASDAQ: WCRX) with a Neutral rating and a $19.00 price target.

Goldman Sachs noted, “We believe WCRX valuation remains undemanding, but greater upside will depend on improved product trends, increased pipeline visibility, or accretive deal activity. We see potential upside to 2H2012 EPS with solid trends for Asacol, Estrace, and the Loestrin franchise supporting revenues, and as the implied second-half spending guidance seems conservative relative to the first-half. However, near-term upside potential does not translate to the long term, with our estimates for 2013 and beyond falling below consensus on a more conservative ramp for Atelvia and the inclusion of a risk adjustment for Asacol given exclusivity uncertainty after a key patent expires in 2013.”

Warner Chilcott closed on Tuesday at $17.54.

Latest Ratings for WCRX

Jul 2013Leerink SwannUpgradesMarket PerformOutperform
Jun 2013JefferiesDowngradesBuyHold
May 2013Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WCRX
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Initiation Analyst Ratings


Related Articles (WCRX)

View Comments and Join the Discussion!

Partner Center